Medtronic has launched its Adaptix Interbody System, which received US Food and Drug Administration (FDA) approval in August, in the US.
Interbody implants are spacers placed between the vertebrae during spinal fusion surgery to minimise the pressure on nerves and to keep the vertebrae in place during the fusion.
Considered to be the first navigated titanium implant with Titan nanoLOCK Surface Technology, Adaptix Interbody System has a proprietary blend of surface textures on the macro, micro, and nano levels.
The Adaptix Interbody System is similar to the Capstone Spinal System. It includes enhanced features for increased strength, subsidence resistance, easy insertion, and data-backed bone growth.
Titan nanoLOCK Surface Technology was developed by Titan Spine , which was acquired by Medtronic last year.
It is the first technology to demonstrate the elements to be considered nanotechnology for spinal devices as suggested in the FDA nanotechnology guidance document.
Medtronic Restorative Therapies Group Core Spine and Biologics division vice-president and general manager Sharrolyn Josse said: “Adaptix Interbody System is an exciting addition to our portfolio that leads with our Titan nanoLOCK Surface Technology. It is a fully navigated procedure, leveraging our leadership in navigation.”
Adaptix Interbody System is compatible with the Medtronic’s StealthStation Navigation and O-arm imaging platform and Grafton DBF Inject, a graft delivery syringe designed to release an osteoinductive DBM into the surgical site.
Last month, Medtronic announced the acquisition of Avenu Medical , a privately held medical device company focused on the endovascular creation of arteriovenous (AV) fistulae for patients with end-stage renal disease (ESRD), undergoing dialysis.